Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivien Hsu

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Medicine|February 3, 2018
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical databaseNadia D Morgan, Ami A Shah, Maureen D Mayes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
The Journal of Rheumatology|February 15, 2007
Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi, Janet E Pope, Philip Clements, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African AmericansPravitt Gourh, Elaine F Remmers, Steven E Boyden, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2019
<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicryPravitt Gourh, Sarah A Safran, Theresa Alexander, et al.
Best Practice & Research. Clinical Rheumatology|September 20, 2021
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SScLesley Ann Saketkoo, Tracy Frech, Cecília Varjú, et al.
Rheumatology (Oxford, England)|September 29, 2022
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive diseaseDavid Roofeh, Kevin K Brown, Ella A Kazerooni, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Clinical and Experimental Rheumatology|December 3, 2016
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registryLorinda Chung, Robert M Fairchild, Daniel E Furst, et al.
Medicine|February 3, 2018
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical databaseNadia D Morgan, Ami A Shah, Maureen D Mayes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic SclerosisRobert Spiera, Masataka Kuwana, Dinesh Khanna, et al.
The Journal of Rheumatology|February 15, 2007
Outcome measurements in scleroderma: results from a delphi exerciseHashim Gazi, Janet E Pope, Philip Clements, et al.
The Lancet. Rheumatology|December 30, 2021
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trialLorinda Chung, Cathie Spino, Richard McLain, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 26, 2019
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled TrialDinesh Khanna, Cathie Spino, Sindhu Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 8, 2018
Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African AmericansPravitt Gourh, Elaine F Remmers, Steven E Boyden, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 25, 2019
<i>HLA</i> and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicryPravitt Gourh, Sarah A Safran, Theresa Alexander, et al.
Best Practice & Research. Clinical Rheumatology|September 20, 2021
A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SScLesley Ann Saketkoo, Tracy Frech, Cecília Varjú, et al.
Rheumatology (Oxford, England)|September 29, 2022
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive diseaseDavid Roofeh, Kevin K Brown, Ella A Kazerooni, et al.
Pageof 4